• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NuVasive Appoints Juliet C. Cunningham as Vice President of Investor Relations

    5/10/21 4:03:00 PM ET
    $NUVA
    Medical/Dental Instruments
    Health Care
    Get the next $NUVA alert in real time by email

    SAN DIEGO, May 10, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Juliet C. Cunningham as the vice president of Investor Relations, effective immediately. In this role, Ms. Cunningham is responsible for the Company's investor relations program and reports directly to Chief Financial Officer Matt Harbaugh.

    NuVasive Logo

    Ms. Cunningham has more than 25 years of experience in investor relations and corporate communications, and most recently was the vice president of Investor Relations at Illumina. Prior to Illumina, she held various investor relations leadership roles at publicly traded companies in the medical device and telecommunications industries. Notably, Ms. Cunningham spent 10 years at QUALCOMM Incorporated where she held various positions with increasing responsibilities in investor relations, corporate communications, and public relations during a period of rapid growth for the company, ultimately serving as senior vice president of Investor Relations.

    "As a well-respected investor relations executive, Juliet's expertise in developing financial communication programs will help advance our strategy and drive further engagement with the investment community," said Mr. Harbaugh. "I look forward to working alongside Juliet and our management team on executing our long-term strategy and fulfilling our vision to change a patient's life every minute."

    Ms. Cunningham holds a bachelor's degree in business administration and completed graduate programs in investor relations and executive leadership at the University of Michigan and Stanford University, respectively. 

    About NuVasive

    NuVasive, Inc. (NASDAQ:NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,700 employees and operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.

    Forward-Looking Statements

    NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-appoints-juliet-c-cunningham-as-vice-president-of-investor-relations-301287015.html

    SOURCE NuVasive, Inc.

    Get the next $NUVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUVA

    DatePrice TargetRatingAnalyst
    2/10/2023$57.72Overweight → Equal Weight
    Wells Fargo
    2/10/2023$63.00 → $52.00Buy → Neutral
    Citigroup
    2/10/2023$51.00 → $52.50Buy → Hold
    Truist
    1/6/2023Buy → Hold
    Needham
    10/18/2022$53.00Overweight
    Barclays
    10/12/2022$45.00Hold
    Jefferies
    4/13/2022$60.00 → $65.00Buy
    Truist
    3/28/2022$58.00Overweight
    Wells Fargo
    More analyst ratings

    $NUVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

      SC 13G/A - NUVASIVE INC (0001142596) (Subject)

      9/11/23 1:33:44 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by NuVasive Inc.

      SC 13G - NUVASIVE INC (0001142596) (Subject)

      2/13/23 3:58:05 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)

      SC 13G/A - NUVASIVE INC (0001142596) (Subject)

      12/6/22 10:35:04 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Wolterman Dan

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 5:06:55 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Raimundo Amy Belt

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 5:04:52 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Norwalk Leslie V returned 3,095 shares to the company, closing all direct ownership in the company

      4 - NUVASIVE INC (0001142596) (Issuer)

      9/5/23 4:55:04 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

      SAN DIEGO, Aug. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 58th Annual Meeting held September 6-9, 2023, in Seattle.  "We partner with esteemed societies like SRS because of our shared dedication to clinical research, education, and thought leadership around advancing patient care, especi

      8/30/23 7:00:00 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600

      NEW YORK, Aug. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 1: Goosehead Insurance Inc. (NASD: GSHD) will replace NuVasive Inc. (NASD: NUVA) in the S&P SmallCap 600. S&P MidCap 400 constituent Globus Medical Inc. (NYSE:GMED) is acquiring NuVasive in a deal expected to close soon pending final conditions.Jackson Financial Inc. (NYSE:JXN) will replace NexTier Oilfield Solutions Inc. (NYSE:NEX) in the S&P SmallCap 600. S&P SmallCap 600 constituent Patterson-UTI Energy Inc. (NASD: PTEN) is acquiring NexTier Oilfield Solutions in a deal expected to close soon pending final cond

      8/28/23 5:41:00 PM ET
      $GMED
      $GSHD
      $JXN
      $NEX
      Medical/Dental Instruments
      Health Care
      Specialty Insurers
      Finance
    • NuVasive Announces Second Quarter 2023 Financial Results

      –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

      8/2/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NuVasive downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded NuVasive from Overweight to Equal Weight and set a new price target of $57.72

      2/10/23 8:01:18 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive downgraded by Citigroup with a new price target

      Citigroup downgraded NuVasive from Buy to Neutral and set a new price target of $52.00 from $63.00 previously

      2/10/23 7:45:41 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive downgraded by Truist with a new price target

      Truist downgraded NuVasive from Buy to Hold and set a new price target of $52.50 from $51.00 previously

      2/10/23 7:45:03 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    SEC Filings

    See more
    • SEC Form 15-12G filed by NuVasive Inc.

      15-12G - NUVASIVE INC (0001142596) (Filer)

      9/11/23 4:46:57 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NuVasive Inc.

      EFFECT - NUVASIVE INC (0001142596) (Filer)

      9/8/23 12:15:09 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by NuVasive Inc.

      EFFECT - NUVASIVE INC (0001142596) (Filer)

      9/8/23 12:15:14 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Financials

    Live finance-specific insights

    See more
    • NuVasive Announces Second Quarter 2023 Financial Results

      –U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

      8/2/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive Announces Conference Call and Webcast of Second Quarter 2023 Results

      SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle

      7/24/23 7:00:00 AM ET
      $NUVA
      Medical/Dental Instruments
      Health Care
    • NuVasive Announces First Quarter 2023 Financial Results

      –Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a

      5/10/23 4:05:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care

    $NUVA
    Leadership Updates

    Live Leadership Updates

    See more
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Blue Spark Technologies Announces Appointment of John DeFord, Ph.D. to its Board of Directors

      The new board member will provide extensive expertise to expand the TempTraq® remote patient monitoring platform Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord's appointment, effective April 13th, 2022, brings the number of board members to five. "This is really an inflection point for the company and it's an exciting time to be involved. I look forward to helping mold the future of their technology," said Dr. DeFord. "I'm particularly excited to see the technology come together that will make an impact in patient's lives." "We are proud to welcome John to

      5/2/22 7:00:00 AM ET
      $NDSN
      $NUVA
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer

      SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022. Mr. Morton brings more than 25 years of experience in human resources, talent development, employee experience, and diversity and inclusion. As CHRO, Mr. Morton will oversee all human resources aspects of the Company

      1/31/22 4:10:00 PM ET
      $NUVA
      Medical/Dental Instruments
      Health Care